1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 19
2 Introduction 20
2.1 Lung Cancer Overview 20
3 Products under Development 21
3.1 Lung Cancer – Pipeline Products by Stage of Development 21
3.2 Lung Cancer – Pipeline Products by Territory 22
3.3 Lung Cancer – Pipeline Products by Regulatory Path 23
3.4 Lung Cancer – Pipeline Products by Estimated Approval Date 24
3.5 Lung Cancer – Ongoing Clinical Trials 25
4 Lung Cancer – Pipeline Products under Development by Companies 26
4.1 Lung Cancer Companies – Pipeline Products by Stage of Development 26
4.2 Lung Cancer – Pipeline Products by Stage of Development 31
5 Lung Cancer Companies and Product Overview 36
5.1 A&G Pharmaceutical Inc Company Overview 36
5.1.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.2 Abbott Diagnostics Company Overview 38
5.2.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 38
5.3 Abcodia Ltd Company Overview 44
5.3.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 44
5.4 Aberystwyth University Company Overview 46
5.4.1 Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 46
5.5 Abnova Corp Company Overview 47
5.5.1 Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 47
5.6 Acobiom Company Overview 48
5.6.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 48
5.7 Advanced Marker Discovery SL Company Overview 50
5.7.1 Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 50
5.8 AIT Austrian Institute of Technology GmbH Company Overview 53
5.8.1 AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 53
5.9 Almac Diagnostic Services Ltd Company Overview 54
5.9.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
5.10 Anixa Diagnostics Corporation Company Overview 56
5.10.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 56
5.11 Armune BioScience Inc Company Overview 61
5.11.1 Armune BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 61
5.12 Aurelium BioPharma Inc. Company Overview 62
5.12.1 Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
5.13 Avant Diagnostics Inc Company Overview 63
5.13.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.14 BARD1 Life Sciences Ltd Company Overview 64
5.14.1 BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 64
5.15 BioAffinity Technologies, Inc. Company Overview 65
5.15.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65
5.16 Biocept Inc Company Overview 68
5.16.1 Biocept Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.17 Biodesix Inc Company Overview 70
5.17.1 Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.18 Biological Dynamics Inc Company Overview 72
5.18.1 Biological Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 72
5.19 BioMark Diagnostics Inc Company Overview 73
5.19.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.20 BioMarker Strategies LLC Company Overview 74
5.20.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 74
5.21 BioNTech SE Company Overview 76
5.21.1 BioNTech SE Pipeline Products & Ongoing Clinical Trials Overview 76
5.22 BioSystems International Company Overview 77
5.22.1 BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 77
5.23 Boston Children’s Hospital Company Overview 78
5.23.1 Boston Children’s Hospital Pipeline Products & Ongoing Clinical Trials Overview 78
5.24 Cancer Genetics Inc Company Overview 79
5.24.1 Cancer Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 79
5.25 Cancer Research Technology Ltd Company Overview 80
5.25.1 Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 80
5.26 Cangen Biotechnologies Inc (Inactive) Company Overview 81
5.26.1 Cangen Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 81
5.27 CDI Laboratories Inc Company Overview 82
5.27.1 CDI Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 82
5.28 Celcuity Inc Company Overview 83
5.28.1 Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 83
5.29 Cellanyx Diagnostics, Inc. Company Overview 84
5.29.1 Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 84
5.30 Cellmid Ltd Company Overview 85
5.30.1 Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 85
5.31 CeMines, Inc. (Inactive) Company Overview 86
5.31.1 CeMines, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 86
5.32 Cepheid Inc Company Overview 87
5.32.1 Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 87
5.33 Ceres Nanosciences Inc Company Overview 89
5.33.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 89
5.34 Cernostics Inc Company Overview 90
5.34.1 Cernostics Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.35 ChemImage Corp Company Overview 91
5.35.1 ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 91
5.36 Clarient Inc Company Overview 92
5.36.1 Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 92
5.37 Courtagen Life Sciences Inc Company Overview 94
5.37.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 94
5.38 Creatv MicroTech Inc Company Overview 95
5.38.1 Creatv MicroTech Inc Pipeline Products & Ongoing Clinical Trials Overview 95
5.39 DiagnoCure Inc. (Inactive) Company Overview 96
5.39.1 DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 96
5.40 EDP Biotech Corporation Company Overview 97
5.40.1 EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 97
5.41 Emory University Company Overview 98
5.41.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 98
5.42 Enterome Bioscience SA Company Overview 99
5.42.1 Enterome Bioscience SA Pipeline Products & Ongoing Clinical Trials Overview 99
5.43 Entopsis LLC Company Overview 100
5.43.1 Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 100
5.44 Epic Sciences Inc Company Overview 101
5.44.1 Epic Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 101
5.45 Epigenomics AG Company Overview 102
5.45.1 Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 102
5.46 Eventus Diagnostics Inc (Inactive) Company Overview 103
5.46.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 103
5.47 Exact Sciences Corp Company Overview 104
5.47.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 104
5.48 Exiqon AS Company Overview 105
5.48.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 105
5.49 Exosome Diagnostics Inc Company Overview 106
5.49.1 Exosome Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 106
5.50 Exosomics Siena SpA Company Overview 107
5.50.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 107
5.51 Fahy Gurteen UK Ltd Company Overview 108
5.51.1 Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 108
5.52 FibroStatin SL Company Overview 109
5.52.1 FibroStatin SL Pipeline Products & Ongoing Clinical Trials Overview 109
5.53 Fina Biotech SL Company Overview 110
5.53.1 Fina Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 110
5.54 French National Institute of Health and Medical Research Company Overview 111
5.54.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 111
5.55 Gene Express, Inc. (Inactive) Company Overview 112
5.55.1 Gene Express, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 112
5.56 GeneCentric Diagnostics, Inc. Company Overview 114
5.56.1 GeneCentric Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
5.57 Genome Profiling LLC Company Overview 115
5.57.1 Genome Profiling LLC Pipeline Products & Ongoing Clinical Trials Overview 115
5.58 Global Discovery Biosciences Corporation Company Overview 116
5.58.1 Global Discovery Biosciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 116
5.59 GlycoZym USA Inc Company Overview 117
5.59.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 117
5.60 Guardant Health Inc Company Overview 118
5.60.1 Guardant Health Inc Pipeline Products & Ongoing Clinical Trials Overview 118
5.61 ImmunePharma Srl Company Overview 121
5.61.1 ImmunePharma Srl Pipeline Products & Ongoing Clinical Trials Overview 121
5.62 ImmunoCellular Therapeutics Ltd Company Overview 122
5.62.1 ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 122
5.63 Immunovia AB Company Overview 123
5.63.1 Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 123
5.64 Insight Genetics Inc Company Overview 126
5.64.1 Insight Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 126
5.65 InterGenetics Inc Company Overview 128
5.65.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 128
5.66 Louisville Bioscience Inc (Inactive) Company Overview 129
5.66.1 Louisville Bioscience Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 129
5.67 Massachusetts General Hospital Company Overview 130
5.67.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 130
5.68 Mayo Clinic Company Overview 131
5.68.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 131
5.69 MDNA Life Sciences Inc Company Overview 132
5.69.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 132
5.70 MDxHealth SA Company Overview 133
5.70.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 133
5.71 MEDITE Cancer Diagnostics Inc Company Overview 134
5.71.1 MEDITE Cancer Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 134
5.72 Memory Dx LLC Company Overview 135
5.72.1 Memory Dx LLC Pipeline Products & Ongoing Clinical Trials Overview 135
5.73 Merrimack Pharmaceuticals Inc Company Overview 136
5.73.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 136
5.74 Metabolon Inc Company Overview 137
5.74.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 137
5.75 Metanomics Health GmbH Company Overview 138
5.75.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 138
5.76 MetaStat Inc Company Overview 139
5.76.1 MetaStat Inc Pipeline Products & Ongoing Clinical Trials Overview 139
5.77 Milagen Inc Company Overview 140
5.77.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 140
5.78 Myriad International GmbH Company Overview 141
5.78.1 Myriad International GmbH Pipeline Products & Ongoing Clinical Trials Overview 141
5.79 Nagoya University Company Overview 142
5.79.1 Nagoya University Pipeline Products & Ongoing Clinical Trials Overview 142
5.80 Nanocytomics LLC Company Overview 143
5.80.1 Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 143
5.81 Nanostics Inc Company Overview 144
5.81.1 Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 144
5.82 NEOMICS Co Ltd Company Overview 145
5.82.1 NEOMICS Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 145
5.83 NovaGray Company Overview 146
5.83.1 NovaGray Pipeline Products & Ongoing Clinical Trials Overview 146
5.84 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 147
5.84.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 147
5.85 Oncimmune (USA) LLC Company Overview 148
5.85.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 148
5.86 OncoCyte Corp Company Overview 151
5.86.1 OncoCyte Corp Pipeline Products & Ongoing Clinical Trials Overview 151
5.87 Oncolome Diagnostics Inc (Inactive) Company Overview 154
5.87.1 Oncolome Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 154
5.88 Onconome, Inc. (Inactive) Company Overview 155
5.88.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 155
5.89 OncoStem Diagnostics Pvt. Ltd Company Overview 156
5.89.1 OncoStem Diagnostics Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 156
5.90 OPKO Health Inc Company Overview 157
5.90.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 157
5.91 Orion Genomics LLC Company Overview 158
5.91.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 158
5.92 OTraces Inc Company Overview 159
5.92.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 159
5.93 Peri Rx Inc Company Overview 160
5.93.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 160
5.94 PleX Diagnostics Inc (Inactive) Company Overview 163
5.94.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 163
5.95 PreMD Inc (Inactive) Company Overview 164
5.95.1 PreMD Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 164
5.96 Proplex Technologies Llc Company Overview 165
5.96.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 165
5.97 Proteome Sciences Plc Company Overview 166
5.97.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 166
5.98 Proteomika (Inactive) Company Overview 167
5.98.1 Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 167
5.99 Quanterix Corp Company Overview 168
5.99.1 Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 168
5.100 Queensland University of Technology Company Overview 170
5.100.1 Queensland University of Technology Pipeline Products & Ongoing Clinical Trials Overview 170
5.101 Research Center Borstel Company Overview 171
5.101.1 Research Center Borstel Pipeline Products & Ongoing Clinical Trials Overview 171
5.102 Roche Diagnostics International Ltd Company Overview 172
5.102.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 172
5.103 Rosetta Genomics Ltd Company Overview 175
5.103.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 175
5.104 Roswell Park Cancer Institute Company Overview 176
5.104.1 Roswell Park Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 176
5.105 Savicell Diagnostic Ltd. Company Overview 177
5.105.1 Savicell Diagnostic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 177
5.106 Sengenics Corp Pte Ltd Company Overview 178
5.106.1 Sengenics Corp Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 178
5.107 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 179
5.107.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 179
5.108 Siemens Healthcare Diagnostics Inc Company Overview 181
5.108.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 181
5.109 Sienna Cancer Diagnostics Ltd Company Overview 184
5.109.1 Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 184
5.110 Simon Fraser University Company Overview 185
5.110.1 Simon Fraser University Pipeline Products & Ongoing Clinical Trials Overview 185
5.111 SomaLogic Inc Company Overview 186
5.111.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 186
5.112 Southern Illinois University Carbondale Company Overview 187
5.112.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 187
5.113 Sysmex Corp Company Overview 188
5.113.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview 188
5.114 Taizhou ZECEN Biotech Co Ltd Company Overview 189
5.114.1 Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 189
5.115 The Prince Charles Hospital Company Overview 190
5.115.1 The Prince Charles Hospital Pipeline Products & Ongoing Clinical Trials Overview 190
5.116 Thermo Fisher Scientific Inc Company Overview 191
5.116.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 191
5.117 Transgene SA Company Overview 192
5.117.1 Transgene SA Pipeline Products & Ongoing Clinical Trials Overview 192
5.118 Treos Bio Inc Company Overview 193
5.118.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 193
5.119 Universal Diagnostics SL Company Overview 194
5.119.1 Universal Diagnostics SL Pipeline Products & Ongoing Clinical Trials Overview 194
5.120 University of California San Francisco Company Overview 195
5.120.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 195
5.121 University of Chicago Company Overview 196
5.121.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 196
5.122 University of Colorado Company Overview 197
5.122.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 197
5.123 University of Maryland Company Overview 198
5.123.1 University of Maryland Pipeline Products & Ongoing Clinical Trials Overview 198
5.124 University of Queensland Company Overview 199
5.124.1 University of Queensland Pipeline Products & Ongoing Clinical Trials Overview 199
5.125 University of South Florida Company Overview 200
5.125.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 200
5.126 University of Texas MD Anderson Cancer Center Company Overview 201
5.126.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 201
5.127 US Biomarkers Inc Company Overview 202
5.127.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 202
5.128 Vanderbilt University Company Overview 203
5.128.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 203
5.129 Ventana Medical Systems Inc Company Overview 204
5.129.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 204
5.130 Viomics Inc. Company Overview 207
5.130.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 207
5.131 VisionGate Inc Company Overview 208
5.131.1 VisionGate Inc Pipeline Products & Ongoing Clinical Trials Overview 208
5.132 VolitionRX Ltd Company Overview 209
5.132.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 209
5.133 XEPTAGEN SpA Company Overview 212
5.133.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 212
5.134 Zetiq Technologies Ltd Company Overview 213
5.134.1 Zetiq Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 213
5.135 ZORA Biosciences Oy Company Overview 214
5.135.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 214
6 Lung Cancer- Recent Developments 215
6.1 Oct 16, 2020: Moffitt researchers develop tool to better predict treatment course for lung cancer 215
6.2 Sep 21, 2020: Takeda and Foundation Medicine to collaborate on cancer diagnostics 215
6.3 Sep 16, 2020: Insmed to host R&D day on September 30, 2020 216
6.4 Sep 15, 2020: Transition to electric vehicles would set america on path to save thousands of lives, avoid billions in healthcare costs 216
6.5 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality 217
6.6 Jul 28, 2020: Thynk Health helps CHI Memorial Chattanooga grow mobile lung screening program 219
6.7 Jul 22, 2020: Cancer Research Institute and the Mark Foundation for Cancer Research launch research collaboration to evaluate liquid biopsy for lung Cancer patient response to immunotherapy 220
6.8 Jul 16, 2020: Improving lung cancer CT screening performance in real-world settings 221
6.9 Jul 15, 2020: New promising treatment uses smart nanoparticles to target lung cancer 222
6.10 Jul 06, 2020: Supporting the discovery of novel blood biomarkers for lung cancer diagnostics 223
6.11 Jun 26, 2020: Sienna Cancer Diagnostics: Change of registered office 225
6.12 Jun 25, 2020: SEC charges Novartis with FCPA violations 225
6.13 Jun 24, 2020: Neural network can determine lung cancer severity 226
6.14 Jun 09, 2020: Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities 226
6.15 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation 227
6.16 May 28, 2020: QIAGEN builds on leading position in Precision Medicine with novel solutions in oncology 227
6.17 May 18, 2020: QIAGEN announces publication of Reasoned Position Statement for proposed acquisition by Thermo Fisher and date for Annual General Meeting 228
6.18 May 13, 2020: OPKO Health’s BioReference Laboratories and Westchester Medical Center Health Network enter into strategic laboratory collaboration to deliver operational and diagnostic services 229
6.19 Apr 29, 2020: Cancer testing and diagnosis suffers sharp downturn, finds Diaceutics 229
6.20 Apr 15, 2020: Indivumed launches global oncology alliance for personalized medicine (“Onco AI-Med”) 230
6.21 Apr 15, 2020: Precision Biologics took $150,000-350,000 PPP government loan for COVID-19-struck small businesses, FOIA request shows 231
6.22 Apr 08, 2020: Immunovia and Global Pharmaceutical Company agree on early termination of lung cancer Collaboration 232
6.23 Apr 03, 2020: StageZero Life Sciences announces publication of abstract at american society of clinical oncology 232
6.24 Mar 20, 2020: Artificial Intelligence may help predict responses to systemic therapies in patients with Non-small Cell Lung Cancer 233
6.25 Mar 12, 2020: Lineage Cell Therapeutics reports fourth quarter and full year 2019 financial results and provides business update 234
6.26 Mar 04, 2020: Oncimmune Holdings: US commercial launch 238
6.27 Mar 03, 2020: Baron & Budd moves forward with false claims act case against AstraZeneca 239
6.28 Feb 29, 2020: MGI’s response to Illumina’s complaint 239
6.29 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors 240
6.30 Feb 27, 2020: Inivata’s Nitzan Rosenfeld to receive 2020 Cancer Researcher Award from the European Association for Cancer Research and Pezcoller Foundation 240
6.31 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 241
6.32 Feb 26, 2020: Mayo Clinic reports ‘remarkable growth’ in 2019 243
6.33 Feb 24, 2020: Oncology Venture & Alpha Blue Ocean mutually terminates agreement with EHGO as part of final financing 243
6.34 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director 244
6.35 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal 244
6.36 Feb 13, 2020: LabCorp announces 2019 fourth quarter and full year results and provides 2020 guidance 244
6.37 Feb 11, 2020: Exact Sciences announces fourth-quarter 2019 results 247
6.38 Feb 10, 2020: New imaging technology shows potential for multiple uses, particularly in medicine 248
6.39 Feb 06, 2020: Agilent Technologies announces Twist Bioscience agrees to pay $22.5 Million settlement in IP litigation 249
6.40 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 250
6.41 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 250
6.42 Feb 05, 2020: Merck announces fourth-quarter and full-year 2019 financial results 251
6.43 Feb 05, 2020: Merck to focus on key growth pillars through spinoff of women’s health, trusted legacy brands and biosimilars products into new company (“newco”) 255
6.44 Feb 05, 2020: GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER) 258
6.45 Feb 03, 2020: Siemens Healthineers starts new fiscal year with strong growth – outlook confirmed 259
6.46 Jan 31, 2020: Benitec Biopharma announces appendix 4C: quarterly cash flow report 261
6.47 Jan 31, 2020: Dr. Christine Seidman and Kathy Warden elected to Merck Board of Directors 262
6.48 Jan 30, 2020: Quest Diagnostics reports record fourth quarter and full year 2019 revenues and earnings; provides guidance for full year 2020; increases dividend
5.7% to $0.56 per quarter 262
6.49 Jan 30, 2020: OGT launches breakthrough NGS panel for constitutional cytogenetics 263
6.50 Jan 29, 2020: Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 264
6.51 Jan 28, 2020: Oncimmune Holdings: EarlyCDT Lung Test more cost effective compared to CT surveillance 270
6.52 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results 271
6.53 Jan 23, 2020: Agilent announces CrossLab Group leadership transition 278
6.54 Jan 22, 2020: Novartis establishes its new legal entity in Vietnam 279
6.55 Jan 22, 2020: GlaxoSmithKline signs agreement to invest £5M in Egypt 279
6.56 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 279
6.57 Jan 13, 2020: Oncocyte announces the commercial availability of DetermaRx, the first test for chemotherapy benefit prediction in patients with early stage non-small cell lung cancer 280
6.58 Jan 13, 2020: HTG Molecular Diagnostics announces preliminary 2019 unaudited financial results 281
6.59 Jan 13, 2020: Enzo Biochem responds to series of misleading and inaccurate statements from activist hedge fund harbert 281
6.60 Jan 12, 2020: Exact Sciences announces preliminary fourth quarter 2019 results 285
6.61 Jan 08, 2020: Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET) 286
6.62 Jan 07, 2020: BioMarker Strategies awarded phase II National Cancer Institute contract to develop novel predictive test for response to immunotherapies for patients with non-small cell lung cancer 287
6.63 Jan 07, 2020: OncoCyte announces successful completion of CLIA validation study of DetermaDx 287
6.64 Jan 06, 2020: Sienna makes Board appointment 288
6.65 Jan 02, 2020: Agilent expands cross-vendor CDS instrument control 288
6.66 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020 289
6.67 Jan 02, 2020: Lineage Cell Therapeutics conducts sale of shares in oncocyte 289
6.68 Dec 31, 2019: Enzo Biochem appoints Rebecca J. Fischer to Board of Directors 290
6.69 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 291
6.70 Dec 29, 2019: Illumina reports financial results for fourth quarter and fiscal year 2019 291
6.71 Dec 24, 2019: Ad-hoc announcement pursuant to article 17 market abuse regulation 293
6.72 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 293
6.73 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 294
6.74 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members 297
6.75 Dec 17, 2019: Case Western Reserve researchers to lead Northeast Ohio initiative to prevent, detect and treat lung cancer in underserved communities 298
6.76 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline 299
6.77 Dec 10, 2019: Enzo Biochem reports fiscal first quarter results 299
6.78 Dec 10, 2019: Siemens Healthineers gives details on second phase of Strategy 2025 and on the further development of its businesses 302
6.79 Dec 05, 2019: VolitionRx and Gyros Protein Technologies awarded an aggregate $1 million+ Eurostars Cash grant to collaborate on developing a Lung Cancer Blood Test 302
6.80 Dec 05, 2019: Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day 303
6.81 Dec 05, 2019: Enzo Biochem issues open letter to shareholders 304
6.82 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 308
6.83 Nov 29, 2019: Immunovia continues with next stage of the Lung Cancer Project together with Global Pharma Partner 309
6.84 Nov 29, 2019: Oncology Venture publishes Interim Report for the period January – September 2019 309
6.85 Nov 28, 2019: One Nucleus announces finalists of the BioNewsRound Award 311
6.86 Nov 27, 2019: ASX/nasdaq announcement: Re-domiciliation to the united states 311
6.87 Nov 26, 2019: LabCorp appoints senior finance executive Jeffrey A. Davis to its Board of Directors 313
7 Appendix 314
7.1 Methodology 314
7.2 About GlobalData 318
7.3 Contact Us 318
